AnaptysBio (ANAB) AI Stock Analysis

• Market Cap: $591.43M
• Dividend Yield: N/A
• Average Volume (3M): 540.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: 387.20%
• EPS Growth: 21.00%
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -1.28
• Shares Outstanding: 29,380,495
• 10 Day Avg. Volume: 425,364
• 30 Day Avg. Volume: 540,065
• PEG Ratio: -0.27
• Price to Book (P/B): 7.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $42.00
• Price Target Upside: 108.64% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 46 Neutral
• Price Target: $20.00 ▼(-0.65%Downside)

AnaptysBio's overall stock score is primarily impacted by its strong revenue growth but significant profitability challenges. The technical indicators suggest moderate positive momentum, which is a positive factor for the stock. However, valuation concerns due to negative earnings and lack of dividend yield weigh down the score. Overall, the financial performance is the most significant factor affecting the score.

Positive Factors

Clinical Trial Success

The Ph. II trial of rosnilimab in RA hit the primary endpoint and demonstrated benefit on key secondary endpoints.

Financial Prospects

ANAB announced a $75M stock repurchase program, representing roughly 12% of the primary shares outstanding.

Strategic Partnerships

GSK reported Jemperli sales significantly above the consensus, which is positive for ANAB due to their financial collaboration.

Negative Factors

Clinical Trial Challenges

ANAB announced that the Ph. IIb trial of ANB032 did not meet the primary EASI-75 endpoint nor any secondary endpoints and will discontinue further development.

Competitive Landscape

Peresolimab was discontinued in Phase 2b by Lilly due to results not aligning with those observed in Phase 2a, contrasting with ongoing trials for rosnilimab.

Financial Performance

Net loss was $38M, compared to an estimated $22M.

AnaptysBio Business Overview & Revenue Model

Company Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

How the Company Makes Money

AnaptysBio generates revenue primarily through strategic collaboration agreements and partnerships with larger pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of specific development, regulatory, and sales objectives, and potential royalty payments on sales of products developed through these partnerships. Additionally, AnaptysBio may receive funding for research and development activities under these partnerships, which further supports its operations. The company's earnings are significantly influenced by the progress and success of its clinical trials, the ability to secure new partnerships, and the commercial success of any licensed products.

AnaptysBio Financial Statement Overview

Summary

AnaptysBio shows strong revenue growth but faces significant profitability challenges and a high reliance on external financing. The balance sheet indicates increasing leverage and declining equity, while cash flow statements reflect substantial negative free cash flow. The company needs to improve operational efficiency and explore revenue growth opportunities to achieve financial sustainability.

Income Statement

AnaptysBio has experienced significant revenue growth from $17.16M in 2023 to $91.28M in 2024, marking a sharp increase. However, the company has consistently reported negative net income, with a net loss of $145.23M in 2024, which indicates ongoing profitability challenges. Gross profit margin remains strong at 100% due to revenue equaling gross profit, but high operating losses are a concern.

Balance Sheet

The company's balance sheet reveals a high debt-to-equity ratio of approximately 0.23 and a decreasing equity base. The equity ratio has decreased from 63.6% in 2020 to 14.6% in 2024, indicating increased leverage. Despite this, the company maintains a strong cash position, which provides some financial flexibility.

Cash Flow

AnaptysBio's cash flow statement highlights a deteriorating free cash flow, with a negative free cash flow of $135.7M in 2024. The operating cash flow to net income ratio is negative, indicating that operating activities are not generating enough cash to support net losses. However, cash inflows from financing activities provide temporary liquidity support.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
91.28M	17.16M	10.29M	63.17M	75.00M
	Gross Profit
91.28M	14.78M	7.95M	-35.32M	-5.03M
	EBIT
-114.95M	-164.41M	-115.15M	-56.81M	-23.88M
	EBITDA
-92.74M	-143.16M	-105.26M	-55.71M	-19.37M
	Net Income Common Stockholders
-145.23M	-163.62M	-128.72M	-57.19M	-19.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
385.37M	390.90M	441.24M	548.10M	393.65M
	Total Assets
483.83M	452.39M	610.38M	643.07M	416.55M
	Total Debt
16.04M	17.81M	19.45M	20.95M	342.00K
	Net Debt
-107.04M	-18.15M	-51.86M	-474.77M	-250.11M
	Total Liabilities
412.97M	364.29M	348.28M	286.64M	19.82M
	Stockholders Equity
70.87M	88.10M	262.10M	356.43M	396.73M
Cash Flow		Free Cash Flow
-135.69M	-121.61M	-73.95M	-47.29M	-14.73M
	Operating Cash Flow
-135.34M	-120.80M	-73.59M	-45.92M	-14.16M
	Investing Cash Flow
95.40M	144.75M	-394.85M	38.84M	94.47M
	Financing Cash Flow
127.05M	-59.30M	44.02M	252.30M	-879.00K

AnaptysBio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 20.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Neutral. The current price of 20.13 is below the 20-day moving average (MA) of 20.51, above the 50-day MA of 19.33, and below the 200-day MA of 23.24, indicating a neutral trend. The MACD of 0.27 indicates Positive momentum. The RSI at 50.13 is Neutral, neither overbought nor oversold. The STOCH value of 50.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ANAB.

AnaptysBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	72 Outperform	$737.61M	―	-6.33%	―	23.92%	-27.69%
TRVI	55 Neutral	$639.97M	―	-55.12%	―	―	-60.26%
Sector *	53 Neutral	$5.14B	3.23	-45.01%	2.85%	17.55%	-0.69%
IMTX	49 Neutral	$599.24M	53.85	-4.52%	―	92.31%	78.17%
ANAB	46 Neutral	$591.43M	―	-343.83%	―	387.20%	21.00%
SVRA	46 Neutral	$490.86M	―	-75.77%	―	―	-44.25%
VALN	45 Neutral	$546.62M	―	-43.77%	―	20.38%	-194.93%

AnaptysBio Corporate Events

AnaptysBio Announces Promising Phase 2b RENOIR Trial Results

On February 12, 2025, AnaptysBio announced significant results from its Phase 2b RENOIR trial for rosnilimab in treating moderate-to-severe rheumatoid arthritis. The trial demonstrated efficacy in key endpoints, including a significant reduction in DAS-28 CRP scores and high CDAI LDA responses, with favorable safety and tolerability profiles, marking a promising advancement in RA treatment.